NYMX - Nymox Pharmaceutical Corporation
3.02 0.00 (0.00%)
After hours: 4:44PM EDT
| Previous Close | 3.09 |
| Open | 3.08 |
| Bid | 3.02 x 3200 |
| Ask | 3.37 x 1000 |
| Day's Range | 3.00 - 3.11 |
| 52 Week Range | 3.00 - 4.60 |
| Volume | 105,913 |
| Avg. Volume | 106,746 |
| Market Cap | 193.762M |
| Beta | 0.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.24 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.25 |
- Associated Press•yesterday
Nymox: 2Q Earnings Snapshot
On a per-share basis, the St. Laurent, Quebec-based company said it had a loss of 4 cents. The biopharmaceutical company posted revenue of $88,000 in the period. In the final minutes of trading on Monday, ...
- GlobeNewswire•last month
NYMOX Announces Expanded Marketing Plans
Nymox Pharmaceutical Corporation (NYMX) announced today that following the recently announced increased manufacturing capabilities, the Company has formally decided to expand its European marketing plans for Fexapotide Triflutate (FT) to all countries in the European Community. Earlier this month Nymox announced that it had successfully accomplished important milestones relating to manufacturing scale-up for FT. Consequently, the Company is now in the enhanced position to have sufficient manufacturing capacities in place to be able to realistically meet anticipated physician demand for FT upon approval.
- GlobeNewswire•2 months ago
NYMOX Successfully Achieves Manufacturing Scale-Up
HASBROUCK HEIGHTS, N.J., June 07, 2018-- Nymox Pharmaceutical Corporation is pleased to report that manufacturing scale-up milestones have been reached for the Company's lead compound Fexapotide Triflutate. ...
- GlobeNewswire•3 months ago
Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association Annual Meeting in San Francisco
Nymox Pharmaceutical Corporation (NYMX) is pleased to report on a successful symposium discussing Nymox’s lead product candidate Fexapotide Triflutate (FT) as a novel therapeutic option in BPH at the Annual Meeting of the American Urological Association in San Francisco, this past weekend. Dr. Ronald Tutrone of Chesapeake Urology Research Associates, Baltimore MD, and a principal investigator in the trials, chaired the meeting and presented clinically relevant therapeutic highlights from the trials.
- Associated Press•3 months ago
Nymox: 1Q Earnings Snapshot
On a per-share basis, the St.-Laurent, Quebec-based company said it had a loss of 5 cents. The biopharmaceutical company posted revenue of $152,000 in the period. The company's shares closed at $3.92. ...
- Simply Wall St.•3 months ago
What You Must Know About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) Major Investors
In this article, I’m going to take a look at Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
- Simply Wall St.•4 months ago
Should You Worry About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) CEO Pay?
Leading Nymox Pharmaceutical Corporation (NASDAQ:NYMX) as the CEO, Paul Averback took the company to a valuation of US$236.27M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
- Simply Wall St.•5 months ago
Should You Have Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) In Your Portfolio?
For Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. NYMX is exposedRead More...
- Simply Wall St.•6 months ago
Interested In Nymox Pharmaceutical Corporation (NASDAQ:NYMX)? Here’s What Its Recent Performance Looks Like
Today I will take a look at Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) most recent earnings update (30 September 2017) and compare these latest figures against its performance over the past fewRead More...
- Capital Cube•9 months ago
Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
Categories: Yahoo FinanceGet free summary analysis Nymox Pharmaceutical Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Nymox Pharmaceutical Corp. – Abbott Laboratories, Eli Lilly and Company, Quest Diagnostics Incorporated, Pfizer Inc., Johnson & Johnson and Sophiris Bio Inc. (ABT-US, LLY-US, DGX-US, PFE-US, JNJ-US and ... Read more (Read more...)
- Simply Wall St.•10 months ago
Nymox Pharmaceutical Corporation (NYMX): How Does It Impact Your Portfolio?
If you are a shareholder in Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
